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Role of CD13 in Chemotaxis of Cytokine-Activated T Cells
Independent of Enzymatic Activity
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Sean C. Friday, Gautam Edhayan, Thomas Lanigan, Andrew Urquhart,
Kevin C. Chung, and David A. Fox
Objective. Aminopeptidase N/CD13 (EC 3.4.11.2)
is a metalloproteinase expressed by fibroblast-like syno-
viocytes (FLS). It has been suggested that CD13 can act
chemotactically for T cells in rheumatoid arthritis (RA).
We undertook this study to measure CD13 in vivo and
in vitro in RA samples and to determine whether CD13
could play a role in the homing of T cells to the RA joint.
Methods. Interleukin-17–treated FLS were used
to immunize mice, from which a novel anti-human CD13
monoclonal antibody (mAb), 591.1D7.34, was developed.
The mAb 591.1D7.34 and a second anti-CD13 mAb,
WM15, were used to develop a novel enzyme-linked
immunosorbent assay (ELISA) for CD13, and CD13
enzymatic activity was measured in parallel. Chemo-
taxis of cytokine-activated T cells was measured by a
chemotaxis-under-agarose assay.
Results. We detected substantial amounts of
CD13 in synovial fluid (SF), sera, FLS lysates, and
culture supernatants by ELISA, with a significant in-
crease in CD13 in RA SF when compared to osteoar-
thritis SF. CD13 accounted for most but not all of the
CD13-like enzymatic activity in SF. Recombinant hu-
man CD13 was chemotactic for cytokine-activated T
cells through a G protein–coupled receptor and contrib-
uted to the chemotactic properties of SF independently
of enzymatic activity.
Conclusion. CD13 is released from FLS into
culture supernatants and is found in SF. CD13 induces
chemotaxis of cytokine-activated T cells, a T cell popu-
lation similar to that found in RA synovium. These data
suggest that CD13 could play an important role as a T
cell chemoattractant, in a positive feedback loop that
contributes to RA synovitis.
Aminopeptidase N/CD13 (EC 3.4.11.2) is a met-
alloproteinase of the M1 family (1–4). It can be found on
the membrane of many cell types (including cells of
monocytic lineage and fibroblasts) and also as a trun-
cated soluble protein (2–6). CD13 is a Zn2-dependent
ectoenzyme that cleaves the N-terminal peptide off
substrates preferentially after a neutral amino acid (2–
4). Substrates of CD13 include enkephalins, angio-
tensins, neurokinins, chemokines, and cytokines, and CD13
may degrade various extracellular matrix (ECM) com-
ponents, aiding in cellular migration (2–4,7,8). CD13 has
also been linked to immune-mediated conditions includ-
ing rheumatoid arthritis (RA), scleroderma, psoriasis,
and chronic graft-versus-host disease (2–4,9–12).
RA is an autoimmune disease characterized by
synovial inflammation and ultimately destruction of
bone and cartilage. Infiltration of lymphocytes is one
essential component of RA synovitis (13). In synovial
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tissue, T cells can interact with other cells (including
fibroblast-like synoviocytes [FLS], macrophages, B cells,
and dendritic cells), leading to cell activation and cyto-
kine secretion (13–15). Various chemokines have been
proposed to attract T cells to the RA joint including
thymus and activation–regulated chemokine (TARC)/
CCL17, interleukin-8 (IL-8)/CXCL8, stromal cell–
derived factor 1 (SDF-1)/CXCL12, and macrophage
inflammatory protein 1/CCL3 (15–17). CD13 involve-
ment in RA has been previously suggested, and phe-
nomena that can be functionally linked to CD13 are seen
in RA (angiogenesis, cellular migration, and monocyte
activation) (2–4,10). However, a definitive role for CD13
in RA has not been shown, and the protein has not
been directly measured. Enzymatic assays of CD13
activity and chemical inhibition of its enzymatic activity
have been used, but neither the assays nor the inhibitors
of CD13 are specific for CD13 versus other aminopep-
tidases (18). Our goals in this study were to measure
CD13 protein in RA and to test the hypothesis that
CD13 in synovial fluid (SF) is chemotactic for T cells.
The results identify soluble CD13 (sCD13) as a protein
that is preferentially produced in the RA joint and has
chemotactic effects on a population of T cells that are
similar to RA synovial T cells, at concentrations found in
SF in vivo.
MATERIALS AND METHODS
Development of 591.1D7.34, a novel anti-CD13 mono-
clonal antibody (mAb). The investigations summarized in this
report began as an approach to defining novel inflammatory
pathways in RA involving FLS, triggered preferentially by
IL-17 rather than by tumor necrosis factor  (TNF). BALB/c
mice were serially immunized with 106 FLS treated with
10 ng/ml IL-17 for 48 hours prior to immunization. A spleen
from the most reactive mouse (assessed by flow cytometry of
FLS using mouse sera) was fused to a nonsecreting myeloma
cell line. The resulting hybridoma clones were screened on
resting FLS and IL-17–treated FLS, and then subcloned. An
osteoarthritis (OA) FLS cell line was biotinylated and lysed.
Immunoprecipitation was used to isolate the protein recog-
nized by mAb 591.1D7.34 (hereafter called 1D7). Controls
included mouse IgG (isotype control) and anti-CD98. The
eluted proteins were electrophoresed under reducing or
nonreducing conditions on a 4–20% Tris–glycine polyacryl-
amide gel. The gel was transferred to an Immobilon-P mem-
brane and incubated with streptavidin–horseradish peroxidase
(HRP) (BioLegend) and then with ECL substrate (Pierce).
U937 myeloid cells were also lysed, and 1D7 was used
to immunoprecipitate a protein which was resolved by electro-
phoresis on 2 identical polyacrylamide gels. One was stained
with Coomassie blue, and the other was excised at a spot
corresponding to the primary band in the stained gel. The
protein was subjected to trypsin digestion in-gel, and the
resulting peptide mixture was analyzed by liquid chromatogra-
phy tandem mass spectrometry on a Qtof premier instrument
(Waters). Protein Lynx Global Server and Mascot search
engines were used to search the UniProt and NCBI databases.
The protein identified matched aminopeptidase N/CD13.
Cell culture. Procedures involving specimens obtained
from human subjects were performed under a protocol ap-
proved by the University of Michigan Institutional Review
Board. Histologic evaluation of synovial tissues was performed
as previously described (19). FLS from human synovial tissue
obtained at arthroplasty or synovectomy from RA or OA joints
were cultured following digestion with 1% collagenase and
separation through a 70 m cell strainer. The diagnosis of RA
required at least 4 American College of Rheumatology 1987
revised criteria (20). The diagnosis of OA was based upon
characteristic clinical and radiographic features. U937 cells
were cultured in RPMI 1640 containing 10% fetal bovine
serum (FBS), 2% L-glutamine, 1% HEPES, 1% sodium pyru-
vate, and 0.5% glucose. FLS were maintained in CMRL
medium (20% FBS, 2 mM L-glutamine, 1% penicillin/
streptomycin) and were used between passages 4 and 10.
Cultures were moved to serum-free media (Dulbecco’s modi-
fied Eagle’s medium [DMEM]/F-12) with PeproGrow serum
replacement (PeproTech) 2 days before harvesting. T cells
were isolated from peripheral blood of healthy subjects using
RosetteSep Human T cell enrichment cocktail (StemCell
Technologies) and Histopaque (Sigma-Aldrich). Cytokine-
activated T cells were prepared by culture of T cells in IL-6
(100 ng/ml), IL-2 (25 ng/ml), and TNF (25 ng/ml) for 7–10
days in 10% FBS/RPMI 1640 medium (21,22). The COS-1 cell
line (ATCC) was grown in 10% FBS/DMEM.
Sample preparation. SF samples were treated for 5
minutes with 0.05% bovine testis hyaluronidase (1 drop per
1 ml of fluid; Sigma-Aldrich). Cells were lysed in cell lysis
buffer (10% Nonidet P40, 10% phenylmethylsulfonyl fluoride,
1% iodoacetamide, and 0.1% E-64 in trichostatin A) for 1 hour
on ice. FLS culture supernatants were concentrated by centrif-
ugation through an Amicon Ultracel 30K filter (Millipore).
Flow cytometry. Fibroblasts were removed from flasks
by 3 mM EDTA in phosphate buffered saline (PBS). Cells
were stained with mouse IgG (negative control) or anti-CD13
(1D7, SJ1D1 [Abcam], or WM15 [BioLegend]) and then with
Alexa Fluor 488–conjugated goat anti-mouse IgG (Molecular
Probes). Cytometry was performed on a FACSCalibur (BD
Biosciences).
Aminopeptidase enzymatic activity. Aminopeptidase
activity was measured by cleavage of L-leucine–7-amido-4-
methyl-coumarin (L-leucine–AMC; Sigma-Aldrich) to release
the fluorescent molecule AMC. A standard curve was con-
structed using AMC (Sigma-Aldrich). The assay was run in
0.1M Tris HCl buffer (pH 8.0). Samples were incubated
with the substrate at 37°C for 1 hour and then read using a
fluorescence plate reader at emission 450 nm, excitation
365 nm. Results were calculated as M/hour of substrate
cleaved.
CD13 enzyme-linked immunosorbent assay (ELISA).
High-binding ELISA plates were coated overnight with the
anti-CD13 monoclonal antibody WM15 in 0.1M carbonate
buffer (pH 9.5) and blocked overnight with 1 Animal Free
Block (Vector). Samples were then applied to the plates either
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whole or diluted in block with 10 mM EDTA. The standard
curve was prepared using recombinant human CD13 (R&D
Systems) in block with 10 mM EDTA. The mAb 1D7 was
biotinylated (Biotin-XX Microscale Protein Labeling kit; Mo-
lecular Probes) and applied overnight. Streptavidin–HRP was
then added. Between steps, the plates were washed with PBS
plus 0.05% Tween. The plates were visualized with tetrameth-
ylbenzidine substrate (BD Biosciences). The reaction was
stopped with 2M H2SO4 and analyzed on a colorimetric plate
reader.
Immunoprecipitation. Immunoprecipitation was per-
formed using a Pierce Direct IP kit (Thermo Scientific).
Briefly, antibodies (anti-CD13 [1D7], anti-CD98 [7F8] [23], or
isotype control [mouse IgG]) were bound to AminoLink Plus
beads (Thermo Scientific) using cyanoborohydride. Samples
were diluted 1:1 with immunoprecipitation lysis/wash buffer
and incubated overnight with the beads. The depleted portion
was removed by centrifugation. Protein was eluted off the
beads by low pH (2.8), which was neutralized with 1M Tris (pH
9.5).
Chemotaxis assay. The chemotaxis assay was a modi-
fied chemotaxis-under-agarose system (24,25). Some plates
were coated overnight at 4°C with 10 g/ml fibronectin then
washed twice with PBS. A 2.4% agarose (UltraPure; Invitro-
gen) solution in 1 Hanks’ balanced salt solution (HBSS) was
boiled and combined with 2 parts 1% bovine serum albumin
(BSA) in RPMI 1640 and 1 part 1 HBSS. Three milliliters of
this solution was added to each well of a 6-well plate and
allowed to cool to room temperature. A 3-hole punch (Uni-
versity of Michigan Instrument Shop) was used to create three
4-mm wells with edges 3 mm apart, and the plates were
equilibrated to 37°C. Chemoattractants and T cells were
adjusted to appropriate concentrations in chemotaxis medium
(0.1% BSA, 2% L-glutamine, 1% penicillin/streptomycin, in
RPMI 1640 without phenol red). Some cytokine-activated T
cell samples were treated for 2 hours at 37°C with 100 ng/ml of
pertussis toxin in 10% RPMI 1640, then washed once with
0.1% BSA in RPMI 1640 (viability 95%). T cells (2.5  105)
were added to the center well. A medium-only control was
added to an outside well, while the chemoattractant solution
was added to the opposite outside well. Plates were incubated
at 37°C in 5% CO2 either overnight (uncoated) or for 5 hours
(fibronectin coated). Pictures were taken of the area directly
between the outside and center wells using an EVOS inverted
microscope at 100 magnification. Cell counts were ln-
transformed, and data are expressed as a chemotactic index
(ln-transformed number of cells migrated to stimulus  ln-
transformed number of cells migrated to medium alone).
CD13 enzymatic mutation. A CD13 clone (MGC
Human ANPEP Sequence-Verified cDNA; GenBank acces-
sion no. BC058928) was obtained from Open Biosystems. An
enzymatically inactive mutant CD13 (E355Q) was created. The
plasmid (1 g DNA) was linearized by double digestion with
Sgr AI (2 units) and Sbf I (10 units) (New England Biolabs).
The 7.3-kb fragment was purified from a 1% agarose gel using
a QIAquick Gel Extraction kit (Qiagen). The plasmid frag-
ment and 2 gene blocks from Integrated DNA Technologies
(5-TGGCCTGCCAGACTTCAACGCCGGCGCCATGCA-
GAACTGGGGACTGGTGACCTACCGGGAGAACTCCC-
TGCTGTTCGACCCCCTGTCCTCCTCCAGCAGCAACA-
AGGAGCGGGTGGTCACTGTGATTGCTCATGAGCTG-
GCCCACCAGTGGTTCGGGAACCTGGTGACCATAGA-
GTGGTGGAATGACCTGTGGCTGAACGAGGGCTTCG-
CCTCCTACGTGGAGTACCTGGGTGCTGACTATGCG-
GAGCCCACCTGGAACTTGAAAGACCTCATGGTGCT-
GAATGA-3 and 5-GACCTCATGGTGCTGAATGATGT-
GTACCGCGTGATGGCAGTGGATGCACTGGCCTCCT-
CCCACCCGCTGTCCACACCCGCCTCGGAGATCAAC-
ACGCCGGCCCAGATCAGTGAGCTGTTTGACGCCAT-
CTCCTACAGCAAGGGCGCCTCAGTCCTCAGGATGC-
TCTCCAGCTTCCTGTCCGAGGACGTATTCAAGCAG-
GGCCTGGCGTCCTACCTCCACACCTTTGCCTACCAG-
AACACCATCTACCTGAACCTGTGGGACCACCTGCA-
GGAGGCTGTGAACAACCGGT-3) were assembled and
transformed into NEB 5-alpha Escherichia coli using a Gibson
Assembly Cloning kit (New England Biolabs).
Clones were selected by ampicillin resistance, and
several colonies were sequenced (University of Michigan Se-
quencing Core) to identify correct clones. Plasmids for wild-
type (WT) CD13 or enzymatically inactive CD13 were grown
and isolated using an EndoFree Plasmid Maxi Kit (Qiagen).
Plasmids were transfected into COS-1 cells using Lipo-
fectamine LTX with Plus Reagent (Life Technologies). Mock
transfection with Lipofectamine alone was used as a control.
Cultures were switched to serum-free SFM4CHO media
(Thermo Scientific) 48 hours after transfection, and cultures
were harvested 24 hours later.
Statistical analysis. Concentrations, percent remain-
ing, and chemotactic index are expressed as the mean  SEM.
Enzymatic activity is expressed as the mean  SD. Statistically
significant chemotaxis was assessed by Student’s paired t-test
comparing the ln-transformed number of cells migrated to
stimulus with the ln-transformed number of cells migrated to
medium alone; an unpaired t-test was used between groups.
Otherwise, significance was determined by Student’s unpaired
t-test, unless otherwise noted.
RESULTS
Identification of CD13 as an IL-17–induced pro-
tein on FLS. To identify a surface structure on FLS that
was regulated by IL-17 independently of TNF, IL-17–
treated FLS were used to immunize BALB/c mice, and
hybridoma clones were created. The clones were
screened on resting FLS, IL-17–treated FLS, and TNF-
treated FLS. A hybridoma was selected that produced
an antibody (591.1D7.34) that recognized an FLS sur-
face protein up-regulated by IL-17 but not by TNF at
48 hours (Figure 1A). Of the cell types tested, the
monocytic cell line, U937, showed the strongest expres-
sion of the molecule identified by 1D7. We therefore
used 1D7 to immunoprecipitate a protein from U937
cells that migrated on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis as a single band of
150 kd, and that was identified as CD13/aminopeptidase
N by sequencing of multiple peptide fragments (Figures
1B and C).
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CD13 in RA in vivo. Having identified FLS CD13
as a potential part of an IL-17–induced pathway, we next
sought to determine whether the concentration of a
putative soluble form of CD13 was elevated in the RA
joint. This was previously suggested by determination of
levels of aminopeptidase activity in SF samples, but
without direct measurement of CD13 protein (9,10). We
developed a novel ELISA to measure CD13 in healthy
control serum samples (n 23), RA serum samples (n
33), and both RA and OA SF samples (n  98). RA SF
samples (n  39) had a mean  SEM CD13 concentra-
tion of 1,191.09  121.58 ng/ml with a mean  SD
activity of 3,402.45  239.58 M/hour, and OA SF
samples (n  59) had a mean  SEM CD13 concentra-
tion of 646.11  45.64 ng/ml and a mean  SD activity
of 2,250.28  93.18 M/hour (Figure 2A). RA SF
samples had significantly higher concentration (P 
0.00001) and activity (P  0.00001). The CD13 concen-
tration in RA SF samples was also significantly higher
than in the 33 RA serum samples (397.95 72.18 ng/ml)
(P  0.00001) and significantly higher than in the 23
healthy control serum samples (683.34  42.41 ng/ml)
(P  0.0023) (Figure 2B).The CD13 concentration was
significantly higher in healthy control serum samples
than in RA serum samples (P  0.0040). The results are
consistent with the observation that IL-17 up-regulates
Figure 1. Identification of the protein recognized by monoclonal antibody 591.1D7.34 (1D7) and up-regulated by interleukin-17 (IL-17) as CD13.
A, Fibroblast-like synoviocytes (FLS) were treated for 48 hours with medium alone, tumor necrosis factor  (TNF), or IL-17 before staining with
1D7 and Alexa Fluor 488–conjugated goat anti-mouse IgG. MCF  mean channel fluorescence. B, An osteoarthritis FLS cell line was biotinylated
and lysed. Immunoprecipitation was used to isolate protein recognized by 1D7, mouse IgG (MsIg; isotype control), or anti-CD98 antibodies that
were bound to beads. Proteins eluted from the beads were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis under reducing
or nonreducing conditions. Protein from the same number of cells was loaded in each lane. C, U937 myeloid cells were lysed, and 1D7 was used to
immunoprecipitate the recognized protein, which was run on 2 gels. One was stained with Coomassie blue, and the other was excised at a spot
corresponding to the primary band in the stained gel. The protein was extracted and multiple peptide fragments were sequenced, each of which
matched portions of aminopeptidase N/CD13 (boldfaced sequences).
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CD13 expression by FLS and lead to the hypothesis that
generation of sCD13 in the RA joint may play a role in
a proinflammatory pathway.
CD13 on RA and OA FLS. Having identified
CD13 on FLS and sCD13 in SF, we asked whether the
difference between RA and OA SF samples corre-
sponded to an increase in CD13 expression by RA FLS.
We used antibodies WM15 and SJ1D1 in addition to
1D7 to measure CD13 by flow cytometry (Figure 3A).
Each antibody detected CD13 on FLS, but with no
significant difference in surface CD13 between resting
RA FLS (n 7) and resting OA FLS (n 5). Moreover,
measurement of total cell CD13 in lysates of RA and
OA FLS by ELISA (P  0.74) and enzymatic activity
assay (P  0.15) showed no significant differences
(Figure 3B). In RA FLS, we found a CD13 concentra-
tion of 4,867.39  1,196.81 ng/ml with an enzymatic
activity of 2,993.65  743.40 M/hour, and in OA FLS,
we found a CD13 concentration of 4,256.74  1,306.71
ng/ml with an enzymatic activity of 2,123.05  1,203.81
M/hour. To determine whether FLS could release
sCD13, we measured CD13 in FLS culture supernatants.
FLS were cultured in serum-free media to eliminate
interference from bovine CD13. Soluble CD13 was
detected by ELISA in the supernatants and was enzy-
matically active, with almost identical results from RA
FLS (51.28 5.15 ng/ml, 957.69 819.02 M/hour) and
OA FLS (50.78 7.16 ng/ml, 962.69 552.26 M/hour)
(Figure 3C).
CD13 and aminopeptidase activity in the joint.
Although we found elevated levels of CD13 protein and
enzymatic activity in RA in vivo, we did not find any
differences in vitro between RA and OA FLS. We next
sought to confirm that the N-aminopeptidase activity
attributed to CD13 in SF samples was really due to
CD13. The correlation between CD13 concentration
and aminopeptidase activity in SF samples was R2 
0.1365 (P  4.24  109 by analysis of variance
[ANOVA]). Considering OA samples separately, the
correlation remained highly significant (R2  0.418, P 
3.17  108 by ANOVA). However, in RA samples, the
correlation was not significant (R2  0.0947, P  0.057
by ANOVA) (Figure 4A). Several outliers could indicate
the variable presence of other proteins with aminopep-
Figure 2. CD13 is found in vivo and its concentrations are higher in rheumatoid arthritis (RA) synovial fluid (SF) than in osteoarthritis (OA) SF.
A, CD13 was measured by enzyme-linked immunosorbent assay (ELISA) in RA SF samples (n 39) and OA SF samples (n 59). CD13 enzymatic
activity was measured in parallel. B, CD13 was measured by ELISA in sera from healthy controls (n  23), in sera from RA patients (n  33), and
in SF samples from RA patients (n  39; not matched to serum). Symbols represent individual samples; bars show the mean.   P  0.05;
  P  0.00001 by one-way analysis of variance.
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tidase activity. To further assess the issue, we immu-
nodepleted RA SF samples (n  6) and OA SF samples
(n 3) using 1D7 and assayed the depleted fractions for
CD13 and aminopeptidase activity. Successful immu-
nodepletion of CD13 (partial or complete) was verified
by ELISA. We showed significant depletion of both
CD13 protein (11.50  0.26% remaining; P  0.00055)
and enzymatic activity (55.74  0.31% remaining; P 
0.0027) (Figure 4B). In most SF samples, the remaining
percentage of aminopeptidase activity was higher than
the remaining percentage of CD13 protein. Moreover,
100% depletion of CD13 protein failed to remove all of
the aminopeptidase activity.
An example in Figure 4C shows 1 RA SF sample
with complete depletion of CD13 as measured by ELISA
in which the enzymatic activity was 876.61  36.06 M/
hour in the isotype control–treated sample and 356.00
17.47 M/hour in the CD13-depleted sample (P 2.3
105). Much of the enzymatic activity in this sample
appeared in the eluate from the 1D7 immunoprecipita-
tion (3,888.00  39.97 M/hour). However, this only
accounted for 60% of the starting enzymatic activity.
Cytokine-activated T cell migration aided by
recombinant human CD13. Having determined that
CD13 is present in high amounts in SF and is enzymat-
ically active, we next considered a possible function of
CD13 in RA. Two previous reports suggested that CD13
is chemotactic for T cells (10,26). We sought to verify
this observation and to determine whether CD13 could
be chemotactic for cytokine-activated T cells, an in
vitro–generated cell population that phenotypically and
functionally resembles T cells found in RA synovium
(21,22). We used a modified chemotaxis-under-agarose
system with SDF-1/CXCL12 and TARC/CCL17 as pos-
itive controls. SDF-1 and TARC had chemotactic indi-
ces of 0.45  0.23 (P  0.068) and 0.42  0.12 (P 
0.0012), respectively, without fibronectin and 0.88 
0.29 (P  0.0046) and 0.46  0.42 (P  0.28), respec-
tively, with fibronectin (Figure 5A). Recombinant hu-
man CD13 was used over a range of concentrations from
1,000 ng/ml to 50 ng/ml and was chemotactic for
cytokine-activated T cells between 700 ng/ml and 50 ng/
ml. Peak chemotaxis for CD13 was from 200 ng/ml
(0.34  0.29) to 500 ng/ml (0.50  0.18) and was
significantly greater than for medium alone (chemotac-
tic index of zero) at both concentrations (P  0.029 and
P  0.0079, respectively). Chemotaxis for recombinant
human CD13 was also significant at 200 ng/ml with
fibronectin coating (0.72 0.29; P 0.018) (Figure 5A).
Representative images of the chemotaxis assays are
Figure 3. Equivalent expression of CD13 by RA fibroblast-like synoviocytes (FLS) and OA FLS. A, FLS were immunostained for CD13 using 3
antibodies (591.1D7.34 [1D7], WM15, SJ1D1) that recognize different epitopes. All 3 showed high expression. Mean fluorescence intensity (MFI)
was adjusted for the isotype control as follows: MFI CD13  MFI mouse IgG  corrected MFI. Values are the mean  SD. B, RA FLS (n  7)
and OA FLS (n  5) were grown to confluence in 20% CMRL medium and switched to serum-free media for 48 hours prior to harvesting. Cells
were lysed, and CD13 was measured by ELISA and enzymatic activity assay. C, The 48-hour culture supernatants were concentrated from 25 ml to
1 ml through a 30-kd centrifugal filter and measured by ELISA and enzymatic activity assay. In B and C, symbols represent individual samples; bars
show the mean. See Figure 2 for other definitions.
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shown in Supplementary Figure 1 (available on the
Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38878/abstract).
CD13 contributes to chemotactic activity of SF
independent of its enzymatic activity. We next investi-
gated whether CD13 contributes to the chemotactic
potential of RA SF. To test for a potential role of CD13
in cytokine-activated T cell chemotaxis, we immunode-
pleted SF samples from 3 different random donors with
anti-CD13 (1D7) or mock-depleted them with an iso-
type control (mouse IgG). The mock-depleted SF sam-
ples had a chemotactic index of 1.37  0.44, which was
significantly chemotactic (P  0.0065). Immunodeplet-
ing CD13 from the SF samples resulted in a significant
Figure 4. CD13 accounts for most but not all of the aminopeptidase activity in SF. A, ELISA and enzymatic activity assay results for RA SF samples
and OA SF samples were correlated separately and together. Correlations were analyzed by analysis of variance: for all points together, R2 0.1365,
P  4.24  109; for OA alone, R2  0.418, P  3.17  108; for RA alone, R2  0.0947, P  0.057. B, SF samples (n  9) were immunodepleted
with anti-CD13 (591.1D7.34 [1D7]), Ig isotype control (mouse IgG; MsIg), or an isotype-matched irrelevant antibody (anti-CD98 [7F8]). The
removed protein was eluted off the beads by low pH. Values are the mean  SEM.   P  0.05;   P  0.001 versus no immunodepletion, by
unpaired 2-tailed t-test. C, Shown is an example of complete depletion of CD13 in an RA SF sample as measured by ELISA; also shown are
corresponding enzymatic activity assay results (n  1 RA SF sample with 3 replicated experiments). Values at left are the mean  SEM; values at
right are the mean  SD.   P  0.0001 by unpaired 2-tailed t-test. See Figure 2 for other definitions.
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Figure 5. CD13 is chemotactic for cytokine-activated T cells independent of its enzymatic activity. Cytokine-activated T cells were placed in the
center well of a chemotaxis-under-agarose system with a medium-only control in one of the side wells and a chemotactic agent in the opposite well.
Some plates were coated with fibronectin. A, Positive wells were loaded with recombinant human CD13 (rhCD13) or with the chemotactic controls
stromal cell–derived factor 1 (SDF-1)/CXCL12 or thymus and activation–regulated chemokine (TARC)/CCL17 (n 12 samples per group). Values
are the mean SEM. B, Positive wells were loaded with SF samples from 3 different random donors. Samples were immunodepleted with anti-CD13
(591.1D7.34 [1D7]) or mock-depleted (Mock) with an isotype control (mouse IgG) at a 1:10 dilution. In addition, CD13-depleted SF samples were
supplemented with supernatant from transfected COS-1 cells containing wild-type (WT) CD13 or enzymatically inactive mutant CD13 (n  19
samples per group). Cell counts were ln-transformed and data are expressed as a chemotactic index (ln-transformed number of cells migrated to
stimulus  ln-transformed number of cells migrated to medium alone). Values are the mean  SEM.   P  0.05 versus medium alone, by paired
2-tailed t-test.   P  0.05 by unpaired 2-tailed t-test. C, The concentration of CD13 in the COS-1 supernatants was determined by ELISA and
was used at 200 ng/ml in assays shown in B. Values are the mean  SEM. Enzymatic activity was measured by N-aminopeptidase activity assay.
Values are the mean  SD. See Figure 2 for other definitions.
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decrease in chemotaxis (to a chemotactic index of 0.35
0.21) (P  0.041) (Figure 5B).
We next examined whether the chemotactic abil-
ity of CD13 required its enzymatic activity. COS-1 cells
were used to express plasmids containing either WT
CD13 or an enzymatically inactive mutant CD13
(E355Q) (27). The CD13 ELISA was used to measure
CD13 concentration, and loss of enzymatic activity in
the mutant was confirmed by the N-aminopeptidase
assay (Figure 5C). We supplemented CD13-depleted SF
samples with 200 ng/ml of either WT or mutant CD13
from the COS-1 supernatants, both of which partially
restored the chemotactic activity of the depleted SF
samples to a similar level. WT CD13 increased the
chemotactic index from 0.35  0.21 to 1.02  0.31, and
mutant CD13 increased the chemotactic index to 1.10 
0.30, each representing significant chemotaxis compared
with medium alone (P  0.0031 and P  0.0018,
respectively) (Figure 5B).
Chemotaxis of T cells initiated by CD13 through
a G protein–coupled receptor (GPCR). Most known
chemokines function through a GPCR (28). We used
pertussis toxin to determine whether the mechanism
for CD13-induced chemotaxis functions similarly. Per-
tussis toxin treatment of cytokine-activated T cells sig-
nificantly reduced chemotaxis for 200 ng/ml of recombi-
nant human CD13 either with a fibronectin coating
(from 0.42 0.20 to0.50 0.50; P 0.047) or without
(from 0.44  0.15 to 0.84  0.44; P  0.00096) and
also inhibited migration toward SDF-1 and TARC-
positive controls (significant for TARC, uncoated, at
P  0.05) (Figure 6).
DISCUSSION
It has become clear that RA is not mediated by a
single cell type but rather by interactions between the
various cells in the RA joint, including FLS and T cells.
RA FLS express matrix metalloproteinases, secrete pro-
inflammatory mediators, and produce chemotactic
agents to attract inflammatory cells to the joint. T cells
are prime producers of multiple proinflammatory cyto-
kines (such as IL-17, TNF, and interferon-). We
explored the potential role of CD13, which is highly
expressed on FLS, as one possible factor in the FLS–T
cell interactions.
Although CD13 has been identified in syn-
ovial fluids by Western blotting and through N-
aminopeptidase enzymatic activity assays, it has never
been directly measured. We developed a novel CD13
ELISA and showed that CD13 concentrations are sig-
nificantly higher in RA SF than in OA SF, healthy
control sera, or RA sera. We also noted a significantly
higher concentration of CD13 in healthy control sera
when compared to RA sera (Figure 2). This could
represent an influx of CD13-expressing cells (such as
monocytes) into the joint, leaving fewer circulating
CD13-shedding cells. We observed higher costaining of
CD13 and a monocytic lineage marker (CD11c) in RA
synovial tissues than in OA or normal synovial tissues
Figure 6. CD13 chemotaxis functions through a pertussis toxin (PTX)–sensitive G protein–coupled receptor. Cytokine-activated T cells (Tcks) were
placed in the center well of a chemotaxis-under-agarose system with a media-only negative control in one of the side wells and a chemotactic
agent (SDF-1, TARC, or recombinant human CD13) at the indicated concentration in the opposite well. Plates were left untreated (A) or were
coated overnight with 10 g/ml fibronectin (B). Some cytokine-activated T cells were treated with 100 ng/ml of pertussis toxin for 2 hours at 37°C
(n 20 samples per group). Cell counts were ln-transformed and data are expressed as a chemotactic index (ln-transformed number of cells migrated
to stimulus ln-transformed number of cells migrated to medium alone). Values are the mean SEM.  P 0.05;  P 0.001 versus medium
alone, by paired 2-tailed t-test.   P  0.05 by unpaired 2-tailed t-test. See Figure 5 for other definitions.
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(see Supplementary Figure 2, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38878/abstract). We were specifically in-
terested in whether FLS could contribute to the sCD13
we found in SF. FLS strongly express surface CD13 and
are therefore a logical choice for shedding of CD13. We
were able to show that sCD13 does come from FLS
(Figure 3C) (see Supplementary Figure 2), and we can
thereby infer that FLS contribute to the sCD13 in SF.
We expected that CD13 would be elevated on RA FLS
as compared to OA FLS, as previously reported (10).
However, our data showed no noticeable difference
(Figure 3). We noted a large variation in the intensity of
CD13 expression on our cell lines and in SF and serum
samples. We believe that this variation may account for
the differences between our results and those previously
reported (10).
There are at least 4 possible explanations for the
higher amount of sCD13 in RA SF than in OA SF. First,
the RA joint environment includes cytokines and growth
factors that could up-regulate CD13 expression or re-
lease from FLS in vivo in a manner that might not be
maintained in vitro (13). This is supported by our finding
that IL-17 increases surface expression of CD13 (Figure
1A). Second, synovial tissue undergoes hyperplasia in
RA, resulting in much higher numbers of FLS that could
release CD13. Third, the increase could be due to other
cell types. Endothelial cells and cells of the monocytic
cell lineage express surface CD13 (2–4). These cells are
often found in higher numbers in the RA joint and so
could account for the increased sCD13. Finally, there is
increased expression of proteases in RA synovium,
which could increase shedding of CD13 from FLS (29).
The most likely explanation for the higher sCD13 in RA
SF combines all 4 possibilities. The complex milieu
present in the RA joint contributes to the higher num-
bers of FLS and other cells as well as the regulation
and shedding of CD13 from those cells, although
monocytic shedding of CD13 has only been observed
previously in apoptotic cells (30).
We wanted to ensure that the aminopeptidase
activity we were measuring could be attributed to CD13.
The mAb 1D7 was used for immunodepletion since it
does not block enzymatic activity (data not shown).
We found that CD13 contributes the majority of
N-aminopeptidase activity to SF; however, it appears
that at least 1 other protein present has similar activity
(Figures 4B and C) (5). The correlation analysis (Figure
4A) showed a few SF samples that also appeared to have
a high concentration of CD13 but lower enzymatic
activity. This could indicate the presence of natural
inhibitors and/or intrinsic differences in the CD13 pro-
tein from posttranslational modifications, resulting in
differing degrees of enzymatic activity.
It was previously suggested that CD13 may act as
a chemokine for T cells (10,26). We wanted to further
explore this function as one possible aspect of the
interaction between FLS and T cells in the RA joint. We
tested for chemotaxis with SDF-1, TARC, or recombi-
nant human CD13 using not only cytokine-activated T
cells, but also resting T cells, anti-CD3/CD28–activated
cells, Jurkat cells, HUT-78 cells, and mitogen-activated
T cells (data not shown). We chose cytokine-activated T
cells because we achieved the most consistent and
significant chemotaxis with both positive control chemo-
kines and recombinant human CD13 with this cell type.
This is of particular interest as cytokine-activated T cells
phenotypically resemble T cells found in the RA joint
(19). Chemotaxis assays with recombinant human CD13
were performed over both a fibronectin-coated plate
and an uncoated plate, to explore both a basic che-
motaxis function (uncoated) and a matrix invasion–type
function (fibronectin coating). Fibronectin improved
adhesion of the cells to the plate, magnifying both
specific and nonspecific movement. Even though recom-
binant human CD13 and SF were significantly chemo-
tactic in both systems, each of the 2 known T cell
chemokines (TARC and SDF-1) was significantly che-
motactic in only 1 of the systems. Nevertheless, the
chemotactic index was similar in both assays, and the
results of these assays are subject to the effects of high
nonspecific background movement.
It is important to note that the optimal levels of
CD13 in the chemotaxis assays corresponded to sCD13
levels found in vivo, indicating that this process is likely
biologically relevant (Figure 5A). Although the average
CD13 concentration in RA SF is higher than the peak
chemotactic range, it is possible that this serves to create
a gradient between the joint and the serum with the high
concentration in the joint aiding in T cell retention.
Consistent with this notion, the average concentration of
CD13 in OA SF was found to be similar to its concen-
tration in normal serum (Figure 2).
It is known that there are multiple chemokines
that contribute to the migration of T cells to the RA
joint (31,32). Notwithstanding the effects of other
chemokines, CD13 appears to contribute significantly to
the chemotactic activity of SF, as cytokine-activated T
cell chemotaxis decreases when CD13 is depleted from
such samples (Figure 5B). CD13 has been shown to be
able to regulate other chemokines, but in vitro studies
with recombinant human CD13 indicate that CD13 can
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initiate chemotaxis directly (33–36). To determine
whether the CD13-dependent chemotaxis in SF oc-
curred directly or through enzymatic effects on other
molecules, we introduced recombinant human CD13
into the depleted SF samples using either WT CD13 or
an enzymatically inactive mutant CD13 (E355Q). This
residue is part of the highly conserved GAMEN motif
that is involved in substrate binding (37,38). Both the
WT and mutant CD13 proteins were able to partially
restore chemotactic activity to a similar degree, demon-
strating that the mechanism of chemotaxis is indepen-
dent of enzymatic activity of CD13 (Figure 5B). This
also indicates that CD13 likely binds directly to a recep-
tor on the T cells. To confirm this, we used pertussis
toxin–treated cytokine-activated T cells. Pertussis toxin
is known to inhibit cellular responses mediated through
Gi/o proteins, including most chemokine receptors
(28,39). We were able to show that CD13 also acts
through a pertussis toxin–sensitive GPCR (Figure 6).
We also saw similar results with a fibronectin coating,
indicating a similar mechanism for basic chemotaxis or
migration involving ECM.
Although we have defined one mechanism for
CD13-mediated T cell chemotaxis in RA, CD13 in the
RA joint is also likely involved in cleaving chemokines,
ECM proteins, and other molecules that regulate migra-
tion of T cells and interaction of those T cells with FLS.
Future investigation of these aspects of CD13 function
and definition of the T cell receptor for CD13 will yield
additional insights into the roles of CD13 in RA.
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